Evidence map›Paper›PMID 38001082›Full record

Trial reportNature communications2023

Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.

Zijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, Rebecca H Boucher, Aimee Jackson, Rachel S Fletcher, Dorian Forte, Jose-Ezequiel Martin, Sonia Fox, James Roberts and 26 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 18 institutions in 1 country.

Zijian FangWellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.
Giuditta Corbizi Fattori *Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.
Thomas McKerrell *Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.ORCID 0000-0003-4235-0650
Rebecca H BoucherCancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Aimee JacksonCancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Rachel S FletcherCancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Dorian ForteWellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.ORCID 0000-0002-8443-605X
Jose-Ezequiel MartinCancer Molecular Diagnostic Laboratory, Department of Oncology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-0051-8868
Sonia FoxCancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
James RobertsDepartment of Haematology, University of Cambridge, Cambridge, UK.
Rachel GloverDepartment of Haematology, University of Cambridge, Cambridge, UK.
Erica HarrisDepartment of Haematology, University of Cambridge, Cambridge, UK.
Hannah R BridgesMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.ORCID 0000-0001-6890-6050
Luigi GrassiDepartment of Haematology, University of Cambridge, Cambridge, UK.
Alba Rodriguez-MeiraNIHR Biomedical Research Centre and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Adam J MeadNIHR Biomedical Research Centre and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID 0000-0001-8522-1002
Steven KnapperSchool of Medicine, Cardiff University, Cardiff, UK.ORCID 0000-0002-6405-4441
Joanne EwingUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Nauman M ButtThe Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK.
Manish JainSt James University Hospital, Leeds, UK.
Sebastian FrancisSheffield Teaching Hospitals NHS Trust, Sheffield, UK.
Fiona J ClarkUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Jason CoppellRoyal Devon and Exeter Hospital, Exeter, UK.
Mary F McMullinQueens University, Belfast, UK.ORCID 0000-0002-0773-0204
Frances WadelinNottingham University Hospital, Nottingham, UK.
Srinivasan NarayananUniversity Hospital Southampton NHSFT, Southampton, UK.
Dragana MilojkovicImperial College Healthcare NHS Trust, London, UK.
Mark W DrummondBeatson West of Scotland Cancer Centre, Glasgow, UK.
Mallika SekharUniversity College Hospital London, London, UK.
Hesham ElDalyCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Judy HirstMRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.ORCID 0000-0001-8667-6797
Maike ParamorWellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.ORCID 0000-0002-8523-3588
E Joanna BaxterDepartment of Haematology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-5946-5238
Anna L GodfreyCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Claire N HarrisonGuy's and Saint Thomas' NHS Foundation Trust, London, UK. Claire.Harrison@gstt.nhs.uk.
Simón Méndez-FerrerWellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK. sm2116@cam.ac.uk.ORCID 0000-0002-9805-9988
University of Cambridge · GBNHS Blood and Transplant · GBCancer Research UK Clinical Trials Unit · GBCambridge University Hospitals NHS Foundation Trust · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity of Oxford · GBBeatson West of Scotland Cancer Centre · GBCardiff University · GBClatterbridge Cancer Centre NHS Foundation Trust · GBGuy's and St Thomas' NHS Foundation Trust · GBImperial College Healthcare NHS Trust · GBQueen's University Belfast · GBRoyal Devon and Exeter Hospital · GBSheffield Teaching Hospitals NHS Foundation Trust · GBSt James's University Hospital · GBUniversity College Hospital · GBUniversity Hospital Southampton NHS Foundation Trust · GBWellcome/MRC Cambridge Stem Cell Institute · GB

Funding

Cancer Research UK 25354Cancer Research UK 26670Cancer Research UK 26988Cancer Research UK 27723Medical Research Council MC_PC_17230Medical Research Council MC_UU_00015/2Medical Research Council MR/V005421/1Wellcome Trust
6 · The paper itself

Abstract

Current therapies for myeloproliferative neoplasms (MPNs) improve symptoms but have limited effect on tumor size. In preclinical studies, tamoxifen restored normal apoptosis in mutated hematopoietic stem/progenitor cells (HSPCs). TAMARIN Phase-II, multicenter, single-arm clinical trial assessed tamoxifen's safety and activity in patients with stable MPNs, no prior thrombotic events and mutated JAK2

Indexed as

Myeloproliferative DisordersNeoplasmsCalreticulinHematopoietic Stem CellsHumansJanus Kinase 2MutationSignal TransductionTamoxifenCalreticulinJanus Kinase 2Tamoxifen

Identifiers

PMID38001082
PMCPMC10673935
OpenAlexW4389001841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.